Neuro Vigor

Executive Summary

Neuro Vigor Therapeutics is a preclinical-stage biotech company pioneering a novel class of small molecule therapies targeting reactive aldehyde species (RAS). Based in San Diego, the company aims to reduce toxic aldehydes that drive oxidative stress, inflammation, and cell damage across multiple diseases, trauma, and pain conditions. Its approach has potential applicability in neurodegenerative, inflammatory, and pain indications, addressing significant unmet medical needs. As a private, development-stage company with no disclosed funding or valuation, Neuro Vigor relies on its proprietary platform to advance lead candidates toward the clinic. The company has not yet filed an IND or initiated clinical trials, reflecting early-stage risk. However, the scientific rationale targeting RAS is emerging, and if successful, could represent a transformative therapeutic class. Near-term progress will depend on securing funding, demonstrating preclinical proof-of-concept, and establishing partnerships.

Upcoming Catalysts (preview)

• Q2 2027Series A Financing or Grant Award40% success
• Q4 2026Preclinical Proof-of-Concept Data in Inflammatory Pain Model55% success
• Q1 2027Identification of Lead Candidate for IND-Enabling Studies50% success